For decades, the process of drug discovery has been a prolonged, costly, and unpredictable endeavor — an effort that ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John: Shardul Nautiyal, Mumbai Friday, January 16, 2026, 08:00 Hrs [IST] Single-Cell Ana ...

HOUSTON, TEXAS / ACCESS Newswire / January 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for ar ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today provided a 2026 corporate outlook and update on key ...

AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, pos ...

Oncology and tackling chronic issues like obesity are still the big drivers for growth in the biotech world. Combining different types of biological data, like genomics and other ‘omics’, will become ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 trial that could lead to approval of the asset in the autoimmune disease.

Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave ...

Augurex CEO Neil Klompas describes why it is difficult for biomarkers to diagnose rheumatoid arthritis in some cases.